A5004919333- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- Immune Cell Function and Interaction
- Chronic Lymphocytic Leukemia Research
- Liver Disease Diagnosis and Treatment
- vaccines and immunoinformatics approaches
- Bacterial Identification and Susceptibility Testing
- CAR-T cell therapy research
- Phagocytosis and Immune Regulation
- Mycobacterium research and diagnosis
- Parkinson's Disease Mechanisms and Treatments
- Patient Satisfaction in Healthcare
- Glioma Diagnosis and Treatment
- Liver Disease and Transplantation
- Neuroinflammation and Neurodegeneration Mechanisms
- Healthcare Policy and Management
- Diverticular Disease and Complications
- Amyotrophic Lateral Sclerosis Research
- Appendicitis Diagnosis and Management
- Cancer therapeutics and mechanisms
- Cardiac, Anesthesia and Surgical Outcomes
- Advanced X-ray and CT Imaging
- Hepatitis C virus research
- Health Systems, Economic Evaluations, Quality of Life
University of South Florida
2021-2023
Rogers (United States)
2023
Daiichi Sankyo (United States)
2023
University of Virginia
2018-2021
Carter Center
2018-2021
Moffitt Cancer Center
2021
Introduction: One of the most pressing goals for cancer immunotherapy at this time is identification actionable antigens. Methods: This study relies on following considerations and approaches to identify potential breast antigens: (i) significant role adaptive immune receptor, complementarity determining region-3 (CDR3) in antigen binding, existence testis antigens (CTAs); (ii) chemical attractiveness; (iii) informing relevance integration items with patient outcome tumor gene expression...
Uterine cancer has been associated with a T-cell immune response that leads to increased survival. Therefore, we used several bioinformatics approaches explore specific interactions between receptor (TCR) and tumor mutant peptide sequences. Using endometrioid uterine exome files from the The Cancer Genome Atlas database, obtained resident V-J recombinations for T-Cell Receptor alpha gene (TRA). charged-based, chemical complementarity each patient's LRP2 or TTN amino acids (AAs) recovered,...
Abstract The Bcl-2 inhibitor venetoclax has yielded exceptional clinical responses in chronic lymphocytic leukemia (CLL). However, de novo resistance can result failure to achieve negative minimal residual disease and predicts poor treatment outcomes. Consequently, additional proapoptotic drugs, such as inhibitors of Mcl-1 Bcl-xL, are development. By profiling antiapoptotic proteins using flow cytometry, we find that leukemic B cells recently emigrated from the lymph node (CD69+/CXCR4Low)...
In the diffuse large B-cell lymphoma (DLBCL) setting, we examined lymph node biopsy, T-cell receptor features, and DLBLC patient human leukocyte antigen (HLA) alleles, to provide a basis for assessing survival distinctions represented by National Cancer Institute Center Research (NCICCR) dataset. While previous analyses of other cancer datasets have indicated that specific (TCR) V or J gene segments, independently, can be associated with distinction, here identified V-J recombinations,...
Glioblastoma (GBM) is the most aggressive primary brain tumor in adults. Despite a growing understanding of glioblastoma pathology, prognosis remains poor.In this study, we used previously extensively benchmarked algorithm to retrieve immune receptor (IR) recombination reads from GBM exome files available cancer genome atlas. The T-cell complementarity determining region-3 (CDR3) amino acid sequences that represent IR were assessed and for generation chemical scores (CSs) potential binding...
Abstract The liver is a site of immune privilege, compared with the bladder and skin, for example. To study this attenuation response in cancer setting, we quantities features adaptive receptor (IR) recombination reads obtained from hepatocellular carcinoma (HCC) six other cancers. Of these cancers, HCC had lowest numbers IR was only greater number immunoglobulin rather than T‐cell reads. better understand role IRs tumor microenvironment shaping outcome cases, quantified chemical...
To better understand how adaptive immune receptors (IRs) in hepatocellular carcinoma (HCC) microenvironments are related to disease outcomes, we employed a chemical complementarity scoring algorithm quantify electrostatic between HCC tumor TRB or IGH complementarity-determining region 3 (CDR3) amino acid (AA) sequences and previously characterized hepatitis C virus (HCV) epitopes. High HCC-resident CDR3s 12 HCV epitopes was associated with greater survival probabilities, as indicated by two...
T-lymphocytes have been implicated in facilitating a pro-inflammatory, pro-tumorigenic microenvironment that worsens prognosis for esophageal carcinoma (ESCA). In this study, we identified tumor resident, T-cell receptor (TCR) complementarity determining region-3 (CDR3) amino acid sequences and employed an algorithm particularly suited to the big data setting evaluate TCR CDR3-cancer testis antigen (CTA) chemical complementarities. Chemical of ESCA CDR3s cancer DDX53 represented disease-free...
Exome and RNAseq files prepared from blood samples can be mined for adaptive immune receptor recombinations thus the complementarity determining region-3 (CDR3) amino acid (AA) sequences, important antigen binding. In this report, T-cell gamma (TRG) were amyotrophic lateral sclerosis (ALS) sample exome files, mainly inspired by: (i) a high level of gamma-delta T-cells in Parkinson’s disease (ii) TRG CDR3 AA features associated with higher Braak stage Alzheimer’s disease. Results indicated...
Responses to ibrutinib (IBR) or venetoclax (VEN) in Chronic Lymphocytic Leukemia (CLL) Mantle Cell Lymphoma (MCL) are often partial. We reported synergistic toxicity for the IBR+VEN combination CLL/MCL ex vivo and initiated an trial MCL (NCT02419560). However, we noted variable de novo resistance even vivo, this has been found patients (Tam et al., 2018). also that microenvironmental agonists (CpG-ODN, sCD40L, IL10; "agonist mix") rapidly induce (Jayappa 2017).Here show multi-drug tolerance...
Abstract Responses to ibrutinib (IBR) or venetoclax (VEN) in Chronic Lymphocytic Leukemia (CLL) Mantle Cell Lymphoma (MCL) are often partial. We reported synergistic toxicity for the IBR+VEN combination CLL/MCL ex vivo and initiated an trial MCL (NCT02419560). However, we noted variable de novo resistance even vivo, this has been found patients (Tam et al., 2018). also that microenvironmental agonists (CpG-ODN, sCD40L, IL10; “agonist mix”) rapidly induce (Jayappa 2017). Here show multi-drug...